Literature DB >> 20074542

Analysis of monoclonal antibody product heterogeneity resulting from alternate cleavage sites of signal peptide.

Ruchi B Kotia1, Anil R Raghani.   

Abstract

Signal peptides used in biosynthesis of proteins are cleaved at a very specific site by signal peptidase during posttranslational translocation of cytoplasmic proteins across the membrane. In some cases, however, there can be cleavage at nonspecific sites, giving rise to heterogeneity in the mature protein, which manifests itself as either elongation or truncation of the N terminus of the mature protein. When used as biopharmaceutical therapeutics, such heterogeneities may be a cause for concern, depending on the nature of the heterogeneity. This article describes the determination of such heterogeneity by peptide mapping in both the heavy chain and the light chain (LC) of a Chinese hamster ovary (CHO) cell-expressed monoclonal antibody (mAb). The peptide map method described here was capable of detecting the extended N-terminal peptides at levels as low as 1% relative to the peak area of the intact N-terminal peptide. The LC of a mAb product was truncated at its N termini by two amino acid residues at approximately 3-4% levels, resulting from alternate signal peptide cleavage. This article describes the quantitation of this truncation by liquid chromatography-mass spectrometry (LC-MS) peptide mapping. Also described is analysis and characterization of LC truncation by reduced and denatured capillary electrophoresis in sodium dodecyl sulfate (CE-SDS). The truncated mAb, which was devoid of the two N-terminal amino acids, was engineered and shown to migrate as the "pre-LC" peak in reduced CE-SDS assay. The amount of the pre-LC peak recovered from the CE-SDS assay was shown to correlate with the amount of truncated peptide observed from the reduced and alkylated peptide map of the engineered mAb. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20074542     DOI: 10.1016/j.ab.2010.01.008

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  11 in total

Review 1.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

2.  Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody.

Authors:  Douglas S Rehder; Chris J Wisniewski; Denfeng Liu; Diya Ren; Dell Farnan; Matthew R Schenauer
Journal:  MAbs       Date:  2018-11-07       Impact factor: 5.857

3.  Discovery, characterization, and remediation of a C-terminal Fc-extension in proteins expressed in CHO cells.

Authors:  Christopher S Spahr; Mark E Daris; Kevin C Graham; Brian D Soriano; Jennitte L Stevens; Stone D-H Shi
Journal:  MAbs       Date:  2018-09-20       Impact factor: 5.857

4.  Characterization of antibody variants during process development: the tale of incomplete processing of N-terminal secretion peptide.

Authors:  Alexandre Ambrogelly; Yan-Hui Liu; Hong Li; Selina Mengisen; Bingyi Yao; Wei Xu; Susan Cannon-Carlson
Journal:  MAbs       Date:  2012-08-29       Impact factor: 5.857

Review 5.  In vitro and in vivo modifications of recombinant and human IgG antibodies.

Authors:  Hongcheng Liu; Gomathinayagam Ponniah; Hui-Min Zhang; Christine Nowak; Alyssa Neill; Nidia Gonzalez-Lopez; Rekha Patel; Guilong Cheng; Adriana Z Kita; Bruce Andrien
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

6.  Identification of a single base-pair mutation of TAA (Stop codon) → GAA (Glu) that causes light chain extension in a CHO cell derived IgG1.

Authors:  Taylor Zhang; Yungfu Huang; Scott Chamberlain; Tony Romeo; Judith Zhu-Shimoni; Daniel Hewitt; Mary Zhu; Viswanatham Katta; Brad Mauger; Yung-Hsiang Kao
Journal:  MAbs       Date:  2012-09-27       Impact factor: 5.857

7.  The C-terminal portion of the cleaved HT motif is necessary and sufficient to mediate export of proteins from the malaria parasite into its host cell.

Authors:  Sarah J Tarr; Adam Cryar; Konstantinos Thalassinos; Kasturi Haldar; Andrew R Osborne
Journal:  Mol Microbiol       Date:  2013-01-21       Impact factor: 3.501

8.  Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells.

Authors:  Ryan Haryadi; Steven Ho; Yee Jiun Kok; Helen X Pu; Lu Zheng; Natasha A Pereira; Bin Li; Xuezhi Bi; Lin-Tang Goh; Yuansheng Yang; Zhiwei Song
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

Review 9.  Molecular and functional analysis of monoclonal antibodies in support of biologics development.

Authors:  Xin Wang; Zhiqiang An; Wenxin Luo; Ningshao Xia; Qinjian Zhao
Journal:  Protein Cell       Date:  2017-07-21       Impact factor: 14.870

10.  Low level sequence variant analysis of recombinant proteins: an optimized approach.

Authors:  Anne Zeck; Jörg Thomas Regula; Vincent Larraillet; Björn Mautz; Oliver Popp; Ulrich Göpfert; Frank Wiegeshoff; Ulrike E E Vollertsen; Ingo H Gorr; Hans Koll; Apollon Papadimitriou
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.